Aerie Pharma (AERI) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil prices, producer inflation ease
- Oil pares losses after reports Houthis attacked Saudi Aramco refinery
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Aegis Capital Notes 'Uneventful' Q3 for Aerie Pharma (AERI); Rhopressa NDA Now Expected in Jan. '17
November 3, 2016 2:37 PM EDTAegis Capital reaffirms Aerie Pharmaceuticals (Nasdaq: AERI) at Buy with a price target of $63 following Q3 results and update issued Wednesday night.
Analyst Difei Yang noted the following on Thursday:
Uneventful Q3. Q3 EPS loss came in at $(0.67) with... More